Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 1,002 put options on the stock. This represents an increase of 1,791% compared to the average volume of 53 put options.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA boosted its stake in Maravai LifeSciences by 11.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 14,150,891 shares of the company’s stock worth $361,273,000 after purchasing an additional 1,459,720 shares during the period. Champlain Investment Partners LLC raised its holdings in shares of Maravai LifeSciences by 0.8% in the 1st quarter. Champlain Investment Partners LLC now owns 3,582,530 shares of the company’s stock valued at $126,356,000 after acquiring an additional 28,405 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Maravai LifeSciences by 4.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,530,561 shares of the company’s stock valued at $100,303,000 after acquiring an additional 135,961 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of Maravai LifeSciences by 11.4% in the 2nd quarter. Clearbridge Investments LLC now owns 2,707,875 shares of the company’s stock valued at $76,931,000 after acquiring an additional 277,260 shares in the last quarter. Finally, Thrivent Financial for Lutherans purchased a new stake in shares of Maravai LifeSciences in the 3rd quarter valued at about $65,350,000. Institutional investors own 48.67% of the company’s stock.
Maravai LifeSciences Price Performance
Shares of NASDAQ:MRVI opened at $13.88 on Thursday. The company has a quick ratio of 6.68, a current ratio of 7.22 and a debt-to-equity ratio of 0.62. Maravai LifeSciences has a twelve month low of $12.16 and a twelve month high of $42.96. The stock’s 50 day moving average is $14.67 and its 200-day moving average is $21.18. The firm has a market capitalization of $3.54 billion, a price-to-earnings ratio of 7.75 and a beta of -0.30.
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The company reported $0.37 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.05. The business had revenue of $191.26 million during the quarter, compared to analyst estimates of $193.83 million. Maravai LifeSciences had a return on equity of 69.19% and a net margin of 26.29%. Sell-side analysts forecast that Maravai LifeSciences will post 1.79 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have commented on MRVI. Credit Suisse Group reduced their price target on shares of Maravai LifeSciences from $34.00 to $26.00 and set an “outperform” rating on the stock in a research report on Thursday, November 3rd. Deutsche Bank Aktiengesellschaft started coverage on shares of Maravai LifeSciences in a research note on Tuesday, December 13th. They issued a “buy” rating and a $25.00 target price for the company. The Goldman Sachs Group cut their target price on Maravai LifeSciences from $30.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, November 4th. Morgan Stanley lowered their price target on Maravai LifeSciences from $35.00 to $32.00 and set an “overweight” rating for the company in a report on Friday, November 4th. Finally, Robert W. Baird decreased their price objective on Maravai LifeSciences from $34.00 to $25.00 in a report on Thursday, November 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.13.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Maravai LifeSciences wasn’t on the list.
While Maravai LifeSciences currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Elon Musk’s Next Move
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Source: news.google.com
